Luke Alexander Robinson

US Patent:

20140056913, Feb 27, 2014

Filed:

Jul 25, 2013

Appl. No.:

13/951066

Inventors:

Luke Nathaniel Robinson - Cambridge MA, US
Kannan Tharakaraman - Arlington MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

C07K 16/10

US Classification:

4241591, 5303894, 5303879, 5303873, 5303883

Abstract:

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.

US Patent:

20200264176, Aug 20, 2020

Filed:

Feb 13, 2020

Appl. No.:

16/790289

Inventors:

- Cambridge MA, US
Luke Nathaniel Robinson - Quincy MA, US
Kannan Tharakaraman - Woburn MA, US

International Classification:

G01N 33/569
C07K 16/10

Abstract:

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.

US Patent:

20180246101, Aug 30, 2018

Filed:

Dec 6, 2017

Appl. No.:

15/833110

Inventors:

- Cambridge MA, US
Luke Nathaniel Robinson - Quincy MA, US
Kannan Tharakaraman - Woburn MA, US

International Classification:

G01N 33/569
C07K 16/10

Abstract:

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.

US Patent:

20180201926, Jul 19, 2018

Filed:

Dec 22, 2017

Appl. No.:

15/852718

Inventors:

- Cambridge MA, US
Gregory Babcock - Marlborough MA, US
Luke Robinson - Quincy MA, US

International Classification:

C12N 15/10
C07K 16/18

Abstract:

Polypeptides, such as antibody molecules and TCR molecules, and methods of making the same, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

US Patent:

20170298119, Oct 19, 2017

Filed:

Apr 14, 2017

Appl. No.:

15/488153

Inventors:

- Cambridge MA, US
Luke Robinson - Quincy MA, US
Gregory Babcock - Marlborough MA, US
Zachary Holmes Shriver - Winchester MA, US

International Classification:

C07K 16/10
A61K 39/12
C12N 7/00
A61K 39/00

Abstract:

Antibody molecules that specifically bind to Zika virus are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose Zika virus infection and disorders associated with Zika virus infection.

US Patent:

20170089898, Mar 30, 2017

Filed:

Oct 12, 2016

Appl. No.:

15/291199

Inventors:

- Cambridge MA, US
Luke Nathaniel ROBINSON - Quincy MA, US
Kannan THARAKARAMAN - Woburn MA, US

International Classification:

G01N 33/569
C07K 16/10

Abstract:

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.